ArriVent Therapeutics
-
Newtown Square’s Arrivent Plans Public Stock Offering to Fund Cancer Drug
ArriVent Biopharma in Newtown Square plans to initiate a public stock offering to raise between $137.5 million and $160 million for the development and launch…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
